329 related articles for article (PubMed ID: 29230662)
21. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Penault-Llorca F; Filleron T; Asselain B; Baehner FL; Fumoleau P; Lacroix-Triki M; Anderson JM; Yoshizawa C; Cherbavaz DB; Shak S; Roca L; Sagan C; Lemonnier J; Martin AL; Roché H
BMC Cancer; 2018 May; 18(1):526. PubMed ID: 29728098
[TBL] [Abstract][Full Text] [Related]
22. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
Asad J; Jacobson AF; Estabrook A; Smith SR; Boolbol SK; Feldman SM; Osborne MP; Boachie-Adjei K; Twardzik W; Tartter PI
Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
[TBL] [Abstract][Full Text] [Related]
23. Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing?
Allison KH; Kandalaft PL; Sitlani CM; Dintzis SM; Gown AM
Breast Cancer Res Treat; 2012 Jan; 131(2):413-24. PubMed ID: 21369717
[TBL] [Abstract][Full Text] [Related]
24. Nottingham-defined mitotic score: comparison with visual and image cytometric phosphohistone H3 labeling indices and correlation with Oncotype DX recurrence score.
Zbytek B; Cohen C; Wang J; Page A; Williams DJ; Adams AL
Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):48-53. PubMed ID: 22495373
[TBL] [Abstract][Full Text] [Related]
25. Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology.
Bello DM; Russell C; McCullough D; Tierno M; Morrow M
Ann Surg Oncol; 2018 Oct; 25(10):2884-2889. PubMed ID: 29968028
[TBL] [Abstract][Full Text] [Related]
26. Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma.
Chang JM; McCullough AE; Dueck AC; Kosiorek HE; Ocal IT; Lidner TK; Gray RJ; Wasif N; Northfelt DW; Anderson KS; Pockaj BA
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S509-15. PubMed ID: 26001860
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Oncotype DX With Modified Magee Equation Recurrence Scores in Low-Grade Invasive Carcinoma of Breast.
Hou Y; Zynger DL; Li X; Li Z
Am J Clin Pathol; 2017 Aug; 148(2):167-172. PubMed ID: 28898988
[TBL] [Abstract][Full Text] [Related]
28. Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast.
Kizy S; Huang JL; Marmor S; Tuttle TM; Hui JYC
Breast Cancer Res Treat; 2017 Oct; 165(3):757-763. PubMed ID: 28647915
[TBL] [Abstract][Full Text] [Related]
29. Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.
Chen C; Dhanda R; Tseng WY; Forsyth M; Patt DA
J Oncol Pract; 2013 Jul; 9(4):182-7. PubMed ID: 23942918
[TBL] [Abstract][Full Text] [Related]
30. Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center.
Loggie J; Barnes PJ; Carter MD; Rayson D; Bethune GC
Breast; 2024 Jun; 75():103715. PubMed ID: 38520994
[TBL] [Abstract][Full Text] [Related]
31. Correlation of Ki-67 proliferative index with oncotype DX recurrence score in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer with low-burden axillary nodal disease - a review of 137 cases.
Saad Abdalla Al-Zawi A; Anichkina KA; Elamass M; Aladili Z
Pol J Pathol; 2024; 75(1):8-18. PubMed ID: 38741425
[TBL] [Abstract][Full Text] [Related]
32. Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.
Biroschak JR; Schwartz GF; Palazzo JP; Toll AD; Brill KL; Jaslow RJ; Lee SY
Breast J; 2013; 19(3):269-75. PubMed ID: 23614365
[TBL] [Abstract][Full Text] [Related]
33. Oncotype DX
Rath MG; Uhlmann L; Fiedler M; Heil J; Golatta M; Dinkic C; Hennigs A; Schott S; Ernst V; Koch T; Sohn C; Brucker C; Rom J
Arch Gynecol Obstet; 2018 Feb; 297(2):443-447. PubMed ID: 29236174
[TBL] [Abstract][Full Text] [Related]
34. Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer.
Tan AC; Li BT; Nahar K; Danieletto S; Fong ES; Currer T; Parasyn A; Middleton P; Wong H; Smart D; Rutovitz JJ; McCloud P; Hughes TM; Marx GM
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e161-e166. PubMed ID: 28960862
[TBL] [Abstract][Full Text] [Related]
35. Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.
Lewin R; Sulkes A; Shochat T; Tsoref D; Rizel S; Liebermann N; Hendler D; Neiman V; Ben-Aharon I; Friedman E; Paluch-Shimon S; Margel D; Kedar I; Yerushalmi R
Breast Cancer Res Treat; 2016 Jun; 157(3):511-6. PubMed ID: 27225387
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Oncotype DX and Mammostrat risk estimations and correlations with histologic tumor features in low-grade, estrogen receptor-positive invasive breast carcinomas.
Acs G; Kiluk J; Loftus L; Laronga C
Mod Pathol; 2013 Nov; 26(11):1451-60. PubMed ID: 23743933
[TBL] [Abstract][Full Text] [Related]
37. Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay.
Gage MM; Mylander WC; Rosman M; Fujii T; Le Du F; Raghavendra A; Sinha AK; Espinosa Fernandez JR; James A; Ueno NT; Tafra L; Jackson RS
Ann Oncol; 2018 May; 29(5):1280-1285. PubMed ID: 29788166
[TBL] [Abstract][Full Text] [Related]
38. Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score.
Chaudhary LN; Jawa Z; Szabo A; Visotcky A; Chitambar CR
Hematol Oncol Stem Cell Ther; 2016 Jun; 9(2):48-54. PubMed ID: 26808222
[TBL] [Abstract][Full Text] [Related]
39. Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.
Chae EY; Moon WK; Kim HH; Kim WH; Cha JH; Shin HJ; Choi WJ; Han W; Noh DY; Lee SB; Ahn SH
PLoS One; 2016; 11(6):e0158461. PubMed ID: 27362843
[TBL] [Abstract][Full Text] [Related]
40. A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas.
Acs G; Esposito NN; Kiluk J; Loftus L; Laronga C
Mod Pathol; 2012 Apr; 25(4):556-66. PubMed ID: 22173289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
